ReportGem ReportGem

U.S. COMPANY FILING

Moderna, Inc. — Form 10-Q filed 2026-07-31

Filed: 2026-07-31Company: Moderna, Inc.Ticker: MRNAExchange: NasdaqForm: 10-QReport period: 2026-06-30SEC accession: 0001682852-26-000150Event: earningsMateriality: 85

Filing text preview

Moderna reported Q2 2026 net loss of $782 million, EPS -$1.97, on revenue of $145 million. H1 revenue was $534 million with net loss of $2.125 billion. Cash and investments totaled $6.9 billion. The company settled litigation with Arbutus and Genevant, accruing $950 million. It also entered a collaboration with Recordati for mRNA-3927, receiving $50 million upfront.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-07-31US Treasury to At Least Double Debt Buybacks; Stock Futures Climb2026-08-20Merck and Moderna's Melanoma Vaccine Trial Positive, Vaccine Themed ETFs Surge2026-08-20S&P 500 and Nasdaq Edge Higher, Led by Moderna and Merck2026-08-20US Stock Index Futures Climb As Yields Cool Off Amid Treasury Support2026-08-20Wall St Rises as Yields Ease, Moderna Lifts Healthcare Stocks2026-08-20Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data, Personalized Cancer Vaccine Meets Goal2026-08-208-K2026-07-31 · 8-K